Back to top
more

Palatin Technologies (PTN)

(Delayed Data from AMEX)

$1.79 USD

1.79
81,274

-0.03 (-1.65%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $1.76 -0.03 (-1.68%) 4:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PTN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Palatin Technologies, Inc. [PTN]

Reports for Purchase

Showing records 41 - 60 ( 194 total )

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

05/17/2021

Company Report

Pages: 7

F3Q21 Results; Vyleesi Hitting Stride Ahead of Likely Partnership; ''9643 About to Go Pivotal

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

02/18/2021

Company Report

Pages: 7

F2Q21 Results; As Vyleesi Rebuilds, Potential Around Other Assets Crystallizes

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

12/15/2020

Company Report

Pages: 7

Dry Eye Disease Goals Achieved; Path to Registration is Next

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

11/18/2020

Company Report

Pages: 7

F1Q21 Results; Data and Hopefully a Partnership Coming Soon

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

09/28/2020

Company Report

Pages: 7

F2020 Results; Eyes Toward Vylessi Re- Licensing; Opportunity Remains After AMAG Drama

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

08/05/2020

Daily Note

Pages: 6

PL9643 Completes the Enrollment of DED Patients; Phase 2 Data Expected in 4Q20

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

07/27/2020

Company Report

Pages: 8

Free at Last; Vyleesi Now Sitting Pretty for Next Steps

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

06/23/2020

Company Report

Pages: 8

Palatin Joins the Fight Against COVID-19-Induced Lung Injury With PL8177

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

05/12/2020

Company Report

Pages: 7

F3Q20 Results; Waiting on Vyleesi Visibility; PL9643 Remains on Track

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

02/19/2020

Daily Note

Pages: 5

PL9643 Enters the Clinic to Tackle Dry Eye Disease

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

02/12/2020

Company Report

Pages: 7

F2Q20 Results; Waiting for Vyleesi to Find Proper Home

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

01/10/2020

Company Report

Pages: 8

AMAG Drama Continues; Target Lowered to $2 Pending Vyleesi Visibility

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

11/13/2019

Company Report

Pages: 8

F1Q20 Results; Vyleesi off to an Early but Impressive Start; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

09/13/2019

Company Report

Pages: 7

F2019 Results; Vyleesi Now Being Marketed; Focus on Key Pipeline Expansion

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

06/24/2019

Company Report

Pages: 7

The Time Has Come for Vyleesi; Next Chapter Begins Plus a $60M Check; Target Increased to $7.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

05/23/2019

Company Report

Pages: 8

AMAG Highlights Vyleesi''s Commercial Profile at Analyst Day; Stage Set for 3Q19 Launch

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

05/23/2019

Company Report

Pages: 8

AMAG Highlights Vyleesi''s Commercial Profile at Analyst Day; Stage Set for 3Q19 Launch

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

05/09/2019

Company Report

Pages: 9

It''s Time to Get Excited; Vyleesi’s PDUFA Is June 23; Target Increased to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

04/04/2019

Company Report

Pages: 6

Vyleesi Data Inserted Into NDA as Expected; PL-8177 Data Bringing up the Rear; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Palatin Technologies, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

02/13/2019

Company Report

Pages: 7

F2Q19 Results; Growing Anticipation Ahead of June PDUFA for Vyleesi; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party